Explore our broad range of B·R·A·H·M·S tumor marker assays
Thermo Fisher Scientific offers a diverse portfolio of Thermo Scientific B·R·A·H·M·S biomarkers built for precision and accuracy, supporting improved management and care for the benefit of your patients.
- B·R·A·H·M·S CgA II KRYPTOR for therapy monitoring of neuroendocrine tumors
- B·R·A·H·M·S AFP KRYPTOR in liver cell carcinoma and testical tumors
- B·R·A·H·M·S CA 125 II KRYPTOR in ovarian cancer
- B·R·A·H·M·S CA 15-3 KRYPTOR in breast cancer
- B·R·A·H·M·S CA 19-9 KRYPTOR in pancreatic and colon cancer
- B·R·A·H·M·S CEA KRYPTOR in colon cancer
- B·R·A·H·M·S CYFRA 21-1 KRYPTOR in non-small cell lung cancer (NSCLC)
- B·R·A·H·M·S NSE KRYPTOR in small cell lung cancer (SCLC)
- B·R·A·H·M·S Total PSA KRYPTOR or B·R·A·H·M·S Total PSA KRYPTOR in prostate cancer
- B·R·A·H·M·S SCC KRYPTOR in cervical cancer and non-small cell lung cancer (NSCLC)
- B·R·A·H·M·S Tg assays and B·R·A·H·M·S Calcitonin RIA in thyroid carcinoma
Choose B·R·A·H·M·S CgA II KRYPTOR: The gold standard for monitoring neuroendocrine tumors
Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR is the first FDA-cleared, automated immunofluorescent assay for the quantitative determination of the concentration of Chromogranin A in human serum.
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.
KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.